Drugs / ABT-288
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00888693 | Nov 2008 → Dec 2009 | schizophrenia | AbbVie | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT01077700 | Mar 2010 → Jul 2011 | — | AbbVie | Completed | No outcome recorded |
| Phase 2 | NCT01018875 | Dec 2009 → Feb 2011 | Alzheimer disease | AbbVie | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABT-288 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01018875 ↗ |
| Action | Inhibit | “Histamine H3 receptor antagonist” CHEMBL3545029 ↗1“histamine-3 receptor antagonist” PMID 24516190 ↗ Feb 2014 |
| Modality | Small molecule | — CHEMBL3545029 ↗ |
| Route | Oral | “administered orally once daily for 14 days” NCT00888693 ↗ |
| Target | HRH3 | “Histamine H3 receptor antagonist” CHEMBL3545029 ↗ |